HPV-ASSOCIATED CANCERS: CERVICAL,
OROPHARYNGEAL, AND ANAL

HPV-driven tumours behave differently from HPV-negative tumours of the same site. In oropharyngeal cancer, HPV-positive disease has substantially better outcomes and is being studied with de-escalation strategies that aim to reduce treatment toxicity. In cervical and anal cancers, HPV positivity is so common that it is assumed in most cases, but biomarker depth — including PD-L1 expression, MSI status, tumour mutation burden, and emerging HPV circulating tumour DNA — increasingly guides treatment in advanced disease. Confirming HPV status through p16 immunohistochemistry and HPV DNA or RNA testing is therefore one of the first steps after diagnosis.

Early-stage disease For very early cervical cancer, fertility-sparing options such as conisation or radical trachelectomy may be appropriate in selected patients. Standard treatment for early invasive disease is radical hysterectomy with pelvic lymph node assessment, often performed robotically or by open surgery depending on tumour size and centre experience. Adjuvant chemoradiation may follow if high-risk pathology features are present. Locally advanced disease For locally advanced cervical cancer, concurrent chemoradiation with cisplatin and external beam radiation followed by brachytherapy is standard, and brachytherapy quality strongly influences outcomes. Pembrolizumab is now added to chemoradiation in selected patients based on improved progression-free survival. Adequate brachytherapy access is one of the most important factors in choosing a treatment centre. Recurrent or metastatic disease First-line therapy for recurrent or metastatic cervical cancer typically combines chemotherapy (paclitaxel plus cisplatin or carboplatin) with bevacizumab and pembrolizumab in PD-L1 positive disease. After progression, options include tisotumab vedotin (an antibody-drug conjugate targeting tissue factor), cemiplimab, and clinical trials. TIL therapy with lifileucel has shown meaningful activity in advanced cervical cancer and is now approved in some regions, with international access continuing to expand.

Early-stage HPV-positive disease Early-stage HPV-positive oropharyngeal cancer is treated with either transoral robotic surgery (TORS) followed by risk-adapted adjuvant therapy, or with radiation alone or chemoradiation. Selection between surgical and non-surgical approaches depends on tumour location, size, nodal involvement, and patient preference. Multiple de-escalation trials are studying whether radiation doses or chemotherapy can be reduced safely in HPV-positive disease. Locally advanced disease Locally advanced oropharyngeal cancer is typically treated with concurrent chemoradiation using cisplatin, or with induction chemotherapy followed by chemoradiation in selected cases. Cetuximab combined with radiation is reserved for patients who cannot tolerate cisplatin, and is generally not preferred for HPV-positive disease where cisplatin remains the standard partner. Proton therapy is increasingly used in selected cases to reduce long-term toxicity to swallowing, salivary, and dental structures. Recurrent or metastatic disease First-line therapy for recurrent or metastatic head and neck squamous cell carcinoma — including HPV-positive oropharyngeal disease — is built around pembrolizumab, used as monotherapy in PD-L1 positive disease (CPS ≥ 1) or in combination with platinum chemotherapy and 5-FU. After progression, nivolumab, cetuximab-based regimens, and clinical trials of HPV-targeted vaccines, TIL therapy, and HPV-specific T-cell therapies become important options.

Localised disease The standard first-line treatment for localised anal squamous cell carcinoma is concurrent chemoradiation with mitomycin and 5-FU (or capecitabine), preserving the anal sphincter and avoiding upfront surgery in most patients. Salvage abdominoperineal resection is reserved for residual or recurrent local disease. Radiation technique matters significantly — IMRT and increasingly proton therapy reduce gastrointestinal and skin toxicity in this technically challenging field. Recurrent or metastatic disease First-line therapy for metastatic anal cancer typically uses carboplatin plus paclitaxel, with retifanlimab or pembrolizumab added in eligible patients based on improved outcomes in HPV-driven disease. After progression, single-agent immunotherapy, clinical trials of HPV-specific T-cell therapy, and TIL approaches are increasingly relevant.

Biomarker testing has become central to advanced HPV-associated cancers. PD-L1 expression by CPS (combined positive score) guides immunotherapy decisions in cervical and head and neck cancers. MSI-H and dMMR status, although uncommon in these cancers, identifies patients with strong immunotherapy responsiveness. Tumour mutation burden, HER2 amplification (relevant in selected gynaecological tumours), and emerging HPV circulating tumour DNA assays for monitoring response and recurrence all add useful information. CancerFax helps patients access reliable PD-L1 IHC, NGS, and HPV-specific testing internationally when local availability is limited.

Case review — diagnosis, HPV and biomarker status, stage, and prior treatment are reviewed to confirm whether the current pathway is optimal. Second opinion coordination — reports are shared with experienced gynaecological, head and neck, or gastrointestinal oncology specialists in India, China, Germany, the United States, and other regions. Biomarker access — if p16, HPV DNA, PD-L1, or NGS testing has not been done, CancerFax helps arrange reliable platforms internationally. Treatment and trial matching — advanced options are mapped to approved regimens, biosimilars, brachytherapy and proton therapy access, TIL therapy programmes, and HPV-targeted clinical trials. Logistics and follow-up — admission, travel, interpreter support, and continuity of care after returning home are coordinated through a single point of contact.

Frequently Asked Questions

Answers to common questions from patients and families.